熱門資訊> 正文
强生公司向FDA提交重症肌无力药物尼波卡利单抗申请
2024-08-29 23:49
- Johnson & Johnson (NYSE:JNJ) said that it has submitted a Biologics License Application (BLA) to the FDA for its drug candidate nipocalimab for the treatment of generalized myasthenia gravis, or gMG.
- The pharmaceutical giant said it was the first global submission for the therapy, according to a statement.
- Argenx (ARGX), UCB and AstraZeneca (AZN) already have drugs on the market to treat MG, a rare autoimmune disease that causes profound muscle weakness and extreme fatigure.
- Other companies working on treatments for the condition include Roche (OTCQX:RHHBY), Alnylam (ALNY), Regeneron (REGN), Dianthus Therapeutics (DNTH), Cartesian Therapeutics (RNAC), Amgen (AMGN) and Immunovant (IMVT).
More on Johnson & Johnson
- Johnson & Johnson: The Dividend King Is Back
- Johnson & Johnson: Don't Bet Against Double Compounding
- 4 Positives For Johnson & Johnson
- Johnson & Johnson continues gains for eight straight sessions
- J&J reportedly seeking additional support for talc bankruptcy plan
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
